These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12142079)

  • 1. Tumor growth inhibition elicited by different vaccines and correlation with antigen specific cytotoxic T-cell frequencies determined by intracellular interferon-gamma staining.
    Johnen H; Pecher G
    Cancer Lett; 2002 Nov; 185(1):53-9. PubMed ID: 12142079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
    Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
    Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.
    Worgall S; Busch A; Rivara M; Bonnyay D; Leopold PL; Merritt R; Hackett NR; Rovelink PW; Bruder JT; Wickham TJ; Kovesdi I; Crystal RG
    J Virol; 2004 Mar; 78(5):2572-80. PubMed ID: 14963160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
    Chen CH; Wang TL; Ji H; Hung CF; Pardoll DM; Cheng WF; Ling M; Wu TC
    Gene Ther; 2001 Jan; 8(2):128-38. PubMed ID: 11313782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
    Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
    J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.
    Ramírez JC; Gherardi MM; Esteban M
    J Virol; 2000 Jan; 74(2):923-33. PubMed ID: 10623755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of cytotoxic T lymphocyte responses against hepatitis delta virus antigens which protect against tumor formation in mice.
    Mauch C; Grimm C; Meckel S; Wands JR; Blum HE; Roggendorf M; Geissler M
    Vaccine; 2001 Oct; 20(1-2):170-80. PubMed ID: 11567762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
    Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid functional exhaustion and deletion of CTL following immunization with recombinant adenovirus.
    Krebs P; Scandella E; Odermatt B; Ludewig B
    J Immunol; 2005 Apr; 174(8):4559-66. PubMed ID: 15814677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
    Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
    Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity of the vaccine-elicited immune response determines tumor clearance.
    Perez-Diez A; Spiess PJ; Restifo NP; Matzinger P; Marincola FM
    J Immunol; 2002 Jan; 168(1):338-47. PubMed ID: 11751979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
    Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
    Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
    Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
    Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake and presentation of exogenous antigen and presentation of endogenously produced antigen by skin dendritic cells represent equivalent pathways for the priming of cellular immune responses following biolistic DNA immunization.
    Sudowe S; Dominitzki S; Montermann E; Bros M; Grabbe S; Reske-Kunz AB
    Immunology; 2009 Sep; 128(1 Suppl):e193-205. PubMed ID: 18800984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.